Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,investments,netBorrowings,repurchaseOfStock,changeToAccountReceivables,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,country,website,maxAge,address1,industry
t0,T5O.DE,17141137.0,4028000,,,-347261,,-347261,213923,9000,-347261,-347261,136818,,,,,0,9000,356261,0,1,,-347261,-347261,59052.0,128692.0,17200189.0,16974.0,17328880.0,3662000.0,3005.0,-17139647.0,11050.0,30677836.0,17242.0,1479205.0,117642.0,30837444.0,18692.0,1526609.0,15707285.0,44399.0,54668.0,0.0,-2000.0,73500.0,4500.0,73500.0,-266000.0,-337500.0,5500.0,-239.0,-2000.0,,,,,,1408967.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.2656958,0,REGULAR,GER,False,False,11.7,1630574796,-0.19999981,12.2,12.2,11.7,2184,-12.717391,2.3013375,15,Europe/Berlin,CEST,2,-1.6806707,11.7 - 12.2,11.9,11.7,12.0,256,1400,finmb_870792,XETRA,CytoTools AG,EUR,4224,7776,0.5999994,0.054054,11.1 - 27.0,-15.3,-0.56666666,11.1,27.0,-0.365,-0.92,7200000,5.084,13.858571,-2.1585712,-0.15575713,15.933451,-4.233451,47127600,CYTOTOOLS  O.N.,0.73,,,27.0,11.1,13.86,15.93,4.22k,7.78k,4.03M,,,38.60%,10.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2019","Jun 30, 2020",0.00%,"-3,689.10%",-4.65%,-8.42%,36.18k,0.01,0.00%,36.18k,-1.31M,-1.4M,-0.37,,1.48M,0.42,,,12.98,5.08,-1.13M,-828.09k,Value,64285,Financial Services,1,"CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.",Darmstadt,Germany,http://cytotools.de,86400,Klappacher Strasse 126,Asset Management
t-1,T5O.DE,17141137.0,4028000,,,-347261,,-347261,213923,9000,-347261,-347261,136818,,,,,0,9000,356261,0,1,,-347261,-347261,59052.0,128692.0,17200189.0,16974.0,17328880.0,3662000.0,3005.0,-17139647.0,11050.0,30677836.0,17242.0,1479205.0,117642.0,30837444.0,18692.0,1526609.0,15707285.0,44399.0,54668.0,0.0,-2000.0,73500.0,4500.0,73500.0,-266000.0,-337500.0,5500.0,-239.0,-2000.0,,,,,,1408967.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.2656958,0,REGULAR,GER,False,False,11.7,1630574796,-0.19999981,12.2,12.2,11.7,2184,-12.717391,2.3013375,15,Europe/Berlin,CEST,2,-1.6806707,11.7 - 12.2,11.9,11.7,12.0,256,1400,finmb_870792,XETRA,CytoTools AG,EUR,4224,7776,0.5999994,0.054054,11.1 - 27.0,-15.3,-0.56666666,11.1,27.0,-0.365,-0.92,7200000,5.084,13.858571,-2.1585712,-0.15575713,15.933451,-4.233451,47127600,CYTOTOOLS  O.N.,0.73,,,27.0,11.1,13.86,15.93,4.22k,7.78k,4.03M,,,38.60%,10.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2019","Jun 30, 2020",0.00%,"-3,689.10%",-4.65%,-8.42%,36.18k,0.01,0.00%,36.18k,-1.31M,-1.4M,-0.37,,1.48M,0.42,,,12.98,5.08,-1.13M,-828.09k,Value,64285,Financial Services,1,"CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.",Darmstadt,Germany,http://cytotools.de,86400,Klappacher Strasse 126,Asset Management
t-2,T5O.DE,17683570.0,4028000,,,-354074,,-354074,78783,9091,-320116,-320116,245484,-33958.0,,,,0,9091,329207,0,-33958,,-354074,-354074,63701.0,110682.0,17747271.0,71632.0,17857951.0,3662000.0,,-16572124.0,,30657395.0,22573.0,2010566.0,110682.0,30828765.0,21459.0,2042933.0,15707285.0,32367.0,,0.0,-255500.0,-30000.0,88000.0,36000.0,-512000.0,-226500.0,5000.0,34074.0,-4500.0,-251000.0,-7500.0,-66000.0,500.0,7500.0,1932251.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.2656958,0,REGULAR,GER,False,False,11.7,1630574796,-0.19999981,12.2,12.2,11.7,2184,-12.717391,2.3013375,15,Europe/Berlin,CEST,2,-1.6806707,11.7 - 12.2,11.9,11.7,12.0,256,1400,finmb_870792,XETRA,CytoTools AG,EUR,4224,7776,0.5999994,0.054054,11.1 - 27.0,-15.3,-0.56666666,11.1,27.0,-0.365,-0.92,7200000,5.084,13.858571,-2.1585712,-0.15575713,15.933451,-4.233451,47127600,CYTOTOOLS  O.N.,0.73,,,27.0,11.1,13.86,15.93,4.22k,7.78k,4.03M,,,38.60%,10.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2019","Jun 30, 2020",0.00%,"-3,689.10%",-4.65%,-8.42%,36.18k,0.01,0.00%,36.18k,-1.31M,-1.4M,-0.37,,1.48M,0.42,,,12.98,5.08,-1.13M,-828.09k,Value,64285,Financial Services,1,"CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.",Darmstadt,Germany,http://cytotools.de,86400,Klappacher Strasse 126,Asset Management
t-3,T5O.DE,17683570.0,4028000,,,-354074,,-354074,78783,9091,-320116,-320116,245484,-33958.0,,,,0,9091,329207,0,-33958,,-354074,-354074,63701.0,110682.0,17747271.0,71632.0,17857951.0,3662000.0,,-16572124.0,,30657395.0,22573.0,2010566.0,110682.0,30828765.0,21459.0,2042933.0,15707285.0,32367.0,,0.0,-255500.0,-30000.0,88000.0,36000.0,-512000.0,-226500.0,5000.0,34074.0,-4500.0,-251000.0,-7500.0,-66000.0,500.0,7500.0,1932251.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.2656958,0,REGULAR,GER,False,False,11.7,1630574796,-0.19999981,12.2,12.2,11.7,2184,-12.717391,2.3013375,15,Europe/Berlin,CEST,2,-1.6806707,11.7 - 12.2,11.9,11.7,12.0,256,1400,finmb_870792,XETRA,CytoTools AG,EUR,4224,7776,0.5999994,0.054054,11.1 - 27.0,-15.3,-0.56666666,11.1,27.0,-0.365,-0.92,7200000,5.084,13.858571,-2.1585712,-0.15575713,15.933451,-4.233451,47127600,CYTOTOOLS  O.N.,0.73,,,27.0,11.1,13.86,15.93,4.22k,7.78k,4.03M,,,38.60%,10.10%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2019","Jun 30, 2020",0.00%,"-3,689.10%",-4.65%,-8.42%,36.18k,0.01,0.00%,36.18k,-1.31M,-1.4M,-0.37,,1.48M,0.42,,,12.98,5.08,-1.13M,-828.09k,Value,64285,Financial Services,1,"CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.",Darmstadt,Germany,http://cytotools.de,86400,Klappacher Strasse 126,Asset Management
